Health‐related quality of life · adults (>= 18 years) with an irreversible visual impairment
1 finding from 1 review
Vision‐related quality of life · adults (>= 18 years) with an irreversible visual impairment
1 finding from 1 review
Adverse events · adults (>= 18 years) with an irreversible visual impairment
1 finding from 1 review
Health‐related quality of life · adults (>= 18 years) with an irreversible visual impairment
1 finding from 1 review
Vision‐related quality of life · adults (>= 18 years) with an irreversible visual impairment
1 finding from 1 review
Adverse events · adults (>= 18 years) with an irreversible visual impairment
1 finding from 1 review
Time to disease progressionMedian · clinically localized prostate cancer
Radical prostatectomy probably leads to lower time to disease progressionMedian compared with active monitoring (moderate certainty).
1 finding from 1 review
Incidence of metastatic diseaseMedian · clinically localized prostate cancer
Radical prostatectomy probably leads to lower incidence of metastatic diseaseMedian compared with active monitoring (moderate certainty).
1 finding from 1 review
Health‐related quality of life · clinically localized prostate cancer
1 finding from 1 review
Urinary function · clinically localized prostate cancer
1 finding from 1 review
Effect on later sexual function · clinically localized prostate cancer
1 finding from 1 review
Time to death from any causeMedian · clinically localized prostate cancer
Radical prostatectomy showed no clear difference in time to death from any causeMedian compared with active monitoring (moderate certainty).
1 finding from 1 review
Time to death from prostate cancerMedian · clinically localized prostate cancer
Radical prostatectomy showed no clear difference in time to death from prostate cancerMedian compared with active monitoring (moderate certainty).
1 finding from 1 review
Symptomatic VTE · ambulatory cancer patients receiving chemotherapy
Low‐molecular‐weight heparin showed no clear difference in symptomatic VTE compared with with active control (1) (low certainty).
3 findings from 1 review
RR 2.89 [0.12, 66.75]
1 study · 51 participants
Low
RR 0.51 [0.22, 1.17]
2 studies · 781 participants
Moderate
RR 0.33 [0.14, 0.83]
1 study · 439 participants
High
Major bleeding · ambulatory cancer patients receiving chemotherapy
The review found no eligible studies for this question.
3 findings from 1 review
Symptomatic PE · ambulatory cancer patients receiving chemotherapy
Low‐molecular‐weight heparin showed no clear difference in symptomatic PE compared with with active control (1); GRADE not reported.
3 findings from 1 review
Symptomatic DVT · ambulatory cancer patients receiving chemotherapy
The review found no eligible studies for this question.
3 findings from 1 review
Total VTE · ambulatory cancer patients receiving chemotherapy
Low‐molecular‐weight heparin showed no clear difference in any VTE compared with with active control (1); GRADE not reported.
3 findings from 1 review
RR 4.81 [0.24, 95.58]
Studies not reported
GRADE not reported
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
1‐year overall mortality · ambulatory cancer patients receiving chemotherapy
The review found no eligible studies for this question.
3 findings from 1 review
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
Clinically relevant bleeding · ambulatory cancer patients receiving chemotherapy
The review found no eligible studies for this question.
3 findings from 1 review
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found